Related Experiment Video
Updated: Mar 30, 2026

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics
Inga-Marie Schaefer1, Christopher Dm Fletcher1, Jason L Hornick1
1Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Abstract:
The diagnosis of malignant peripheral nerve sheath tumor is challenging, particularly in the sporadic setting. Inactivation of the polycomb repressive complex 2 (PRC2), resulting from inactivating mutations of its constituents SUZ12 or EED1, has recently been identified in 70-90% of malignant peripheral nerve sheath tumors. Homozygous PRC2 inactivation results in loss of histone H3K27 trimethylation (H3K27me3). PRC2 inactivation promotes tumor progression and may render patients sensitive to epigenetic-based targeted therapies. H3K27me3 loss has not yet been validated as a diagnostic marker. We evaluated immunohistochemistry for H3K27me3 in 100 malignant peripheral nerve sheath tumors (70 sporadic, 10 neurofibromatosis type 1-associated, 10 radiation-associated, 10 epithelioid) and 200 other spindle cell neoplasms representing potential mimics (20 each monophasic synovial sarcoma, leiomyosarcoma, dedifferentiated liposarcoma, malignant solitary fibrous tumor, low-grade fibromyxoid sarcoma, cellular schwannoma, spindle cell melanoma, unclassified postradiation sarcoma; 10 each atypical neurofibroma, spindle cell rhabdomyosarcoma, gastrointestinal stromal tumor, fibrosarcomatous dermatofibrosarcoma protuberans). In total, 51 (51%) malignant peripheral nerve sheath tumors, including 34 (49%) sporadic, 7 (70%) neurofibromatosis type 1-associated, and 10 (100%) radiation-associated, but no epithelioid malignant peripheral nerve sheath tumors, were negative for H3K27me3. An additional 6 (6%) tumors showed heterogeneous H3K27me3 expression. Among the 90 sporadic, neurofibromatosis type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors, complete H3K27me3 loss was observed in 29% of low-grade, 59% of intermediate-grade, and 83% of high-grade tumors (low vs intermediate/high grade, P=0.0003). Among other tumor types, 4 (20%) unclassified postradiation sarcomas were negative for H3K27me3, whereas all other neoplasms were positive. Loss of H3K27me3 is highly specific for malignant peripheral nerve sheath tumor (although only modestly more sensitive than S-100 protein and SOX10) and may be a useful diagnostic marker. Our findings suggest that PRC2 inactivation in malignant peripheral nerve sheath tumor may occur during progression to higher grades.
Insights
Loss of histone H3K27 trimethylation (H3K27me3) is a specific marker for malignant peripheral nerve sheath tumors. This epigenetic alteration may indicate tumor progression and potential sensitivity to targeted therapies.
Area of Science:
- Oncology
- Epigenetics
- Molecular Pathology
Background:
- Malignant peripheral nerve sheath tumors (MPNSTs) pose diagnostic challenges, especially in sporadic cases.
- Inactivation of Polycomb Repressive Complex 2 (PRC2) is frequent in MPNSTs, leading to loss of H3K27me3.
- H3K27me3 loss is a potential diagnostic marker for MPNSTs.
Purpose of the Study:
- To validate immunohistochemistry for H3K27me3 as a diagnostic marker for MPNSTs.
- To assess the correlation between H3K27me3 loss and tumor grade and type.
- To investigate the role of PRC2 inactivation in MPNST progression.
Main Methods:
- Immunohistochemistry for H3K27me3 was performed on 100 MPNSTs and 200 other spindle cell neoplasms.
- MPNSTs included sporadic, neurofibromatosis type 1-associated, radiation-associated, and epithelioid subtypes.
- Comparison of H3K27me3 expression across different tumor types and grades.
Main Results:
- 51% of MPNSTs showed complete H3K27me3 loss; 6% had heterogeneous expression.
- H3K27me3 loss was observed in 49% of sporadic, 70% of NF1-associated, and 100% of radiation-associated MPNSTs.
- Complete H3K27me3 loss increased with tumor grade (29% low, 59% intermediate, 83% high grade).
- Four unclassified postradiation sarcomas also showed H3K27me3 negativity; all other mimics were positive.
- H3K27me3 loss demonstrated high specificity for MPNSTs.
Conclusions:
- Loss of H3K27me3 is a highly specific marker for MPNSTs, aiding in diagnosis.
- PRC2 inactivation and subsequent H3K27me3 loss may occur during MPNST progression to higher grades.
- H3K27me3 loss could guide epigenetic-based targeted therapies for MPNST patients.
More Related Videos
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021